Several other equities analysts have also recently weighed in on the company. Northland Securities restated a buy rating and set a $40.00 price objective on shares of Aridis Pharmaceuticals in a research note on Tuesday, July 30th. Zacks Investment Research upgraded Aridis Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, July 16th. Finally, Maxim Group restated a buy rating on shares of Aridis Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Aridis Pharmaceuticals has an average rating of Buy and an average target price of $27.50.
NASDAQ:ARDS traded up $0.65 during trading hours on Thursday, hitting $8.45. 283 shares of the company traded hands, compared to its average volume of 3,822. The business’s 50-day simple moving average is $9.71. Aridis Pharmaceuticals has a one year low of $6.91 and a one year high of $13.85.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Featured Article: What is meant by holder of record?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.